Amgen Inc.

AMGN

US0311621009

Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows: - drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.; - other (5.8%): primarily royalties. The United States account for 70.6% of net sales.

Sector

Pharmaceuticals

Calendar

09:10am - Evercore ISI HealthCONx Conference

More about the company

Income Statement Evolution

More financial data

Ratings for Amgen Inc.

Trading Rating :

Investor Rating :

ESG Refinitiv :

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

265.52USD

Average target price

276.06USD

Spread / Average Target

+3.97%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi. (M$)
AMGEN INC.	+1.64%	142 B $
ELI LILLY AND COMPANY	+60.79%	532 B $
NOVO NORDISK A/S	+46.38%	452 B $
JOHNSON & JOHNSON	-14.04%	365 B $
MERCK & CO., INC.	-9.92%	254 B $
ABBVIE INC.	-14.46%	244 B $
ROCHE HOLDING AG	-18.73%	216 B $
NOVARTIS AG	+1.40%	200 B $
ASTRAZENECA PLC	-10.86%	195 B $
PFIZER, INC.	-41.30%	168 B $

Other Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 10:10:32 2023-11-29 am EST			5-day change	1st Jan Change
266.85 ^USD	+0.50%		+0.89%	+1.64%

Nov. 20	Wegovy craze was all the rage on Q3 earnings calls	RE
Nov. 16	Amgen's Rights to Bempikibart Regained by Q32 Bio	MT

Wegovy craze was all the rage on Q3 earnings calls	Nov. 20	RE
Amgen's Rights to Bempikibart Regained by Q32 Bio	Nov. 16	MT
U.S. Currency	Nov. 15	FA
Investors increase holdings of weight-loss drug makers' shares in Q3 -filings	Nov. 14	RE
Novo Nordisk shares rise as Wegovy shows heart benefits beyond weight loss	Nov. 13	RE
Wall Street: a surge in interest rates breaks the bullish rally	Nov. 10	CF
Reuters NEXT-Investment bankers see dealmaking lull storing pent-up demand	Nov. 09	RE
Deutsche Bank Initiates Coverage on Amgen With Hold Rating, $240 Price Target	Nov. 09	MT
Amgen Presents New Data from Phase 2 Trial of Dazodalibep in Sjogren's Syndrome at ACR 2023	Nov. 07	CI
North American Morning Briefing : S&P 500 Futures -2-	Nov. 03	DJ
Truist Securities Upgrades Amgen to Buy From Hold With $320 Price Target	Nov. 02	MT
RBC Raises Price Target on Amgen to $256 From $253, Keeps Sector Perform Rating	Nov. 02	MT
Amgen Inc. Presents New Data That Show Blood Pressure Decides for Results Treated with Krystexxa (PegLOTICase)	Nov. 02	CI
Amgen's Emerging Pipeline is Deserving of Greater Clarity, RBC Capital Markets Says	Nov. 01	MT
UBS Cuts Amgen Price Target to $268 From $272, Maintains Neutral Rating	Nov. 01	MT
Morgan Stanley Adjusts Amgen Price Target to $291 From $300, Maintains Equal Weight Rating	Nov. 01	MT
RBC Raises Price Target on Amgen to $256 From $253, Cites 'Clarity Emerging' on Pipeline, Keeps Sector Perform Rating	Nov. 01	MT
Amgen Gets FDA Approval for Inflammatory Diseases Treatment	Oct. 31	DJ
U.S. FDA approves Amgen's biosimilar version of J&J's psoriasis drug	Oct. 31	RE
U.S. FDA approves Amgen's biosimilar vesrion of J&J's Stelara	Oct. 31	RE
Wall Street closes higher on eve of Fed decision	Oct. 31	RE
Health Care Up Slightly Amid Mixed Earnings -- Health Care Roundup	Oct. 31	DJ
Wall St closes higher on eve of Fed decision; investors assess earnings	Oct. 31	RE
Wall St up slightly before Fed decision; investors assess earnings	Oct. 31	RE
Amgen Discontinues Trial of Investigational Prostate Cancer Treatment AMG 340	Oct. 31	MT